38. The use of an inhibitor according to any of claims 35 to 37, having a heavy chain comprising the sequence given in SEQ ID NO:9 and a light chain comprising the sequence given in SEQ ID NO:7.

39. The use of an inhibitor according to any one of claims 25 to 38, wherein the antibody or fragment or derivative thereof having a binding affinity [K_D] for human CSF-1R of 10pM or less than 10pM.

40. The use of an inhibitor according to any one of claims 25 to 39, wherein the antibody or fragment or derivative thereof cross-blocks the binding of an antibody according to claim 13 with an affinity [K_D] of 100pM or less.

41. The use of an inhibitor according to any of claims 25 to 40, wherein the antibody or fragment or derivative thereof cross-blocks the binding by binding the same epitope as the antibody which it blocks.

42. The use of an inhibitor according to any one of claims 25 to 41, wherein the antibody or fragment or derivative thereof competes with the antibody or fragment or derivative thereof of claim 35 for binding to the extracellular domain of human c-fms of SEQ ID NO: 15.

43. The use of an inhibitor according to any one of claims 25 to 42, which binds to the epitope of human CSF-1R as the inhibitor of claim 35.

44. The use of an inhibitor of claim 24 which is an isolated DNA sequence encoding the heavy and/or light chain(s) of an antibody according to any one of claims 35 to 43.

45. A pharmaceutical composition comprising an inhibitor according to any of claims 1 to 22, in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.

46. A pharmaceutical composition according to claim 45, additionally comprising other active ingredients.

47. Use of a therapeutically effective amount of an inhibitor of CSF-1R activity in the manufacture of a medicament for the treatment and/or prophylaxis of a human subject suffering from or at risk of neurologic disease.

48. The use according to claim 47, comprising use of a therapeutically effective amount of an inhibitor according to any of claims 1 to 22, or a pharmaceutical composition according to claims 45 or 46.

49. The use according to any one of claims 47 or 48, where the inhibitor of CSF-1R activity is to be administered in combination with one or more other therapeutically active compounds.

50. The use according to claim 49, in which the other therapeutically active compound is another anti-epileptic therapeutic agent.

51. The inhibitor for use according to any of claims 1 to 22, the use according to any of claims 23 to 44, the pharmaceutical composition according to any of claims 45 or 46 or the use according to any of claims 47 to 50, wherein the neurologic disease is selected from the group consisting of Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Angelman syndrome, Attention deficit hyperactivity disorder, Autism spectrum, Bipolar disorder, Brain damage, Brain injury, Brain tumor, Central pain syndrome, Cerebral atrophy, Chronic inflammatory demyelinating polyneuropathy (CIDP), Chronic pain, Complex regional pain syndrome, Creutzfeldt-Jakob disease, Dementia, Down syndrome, Dravet syndrome, Encephalitis, Essential tremor, Friedreich's ataxia, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Head injury, Headache, Herpes zoster, Huntington's disease, Hypoxia, Immune-Mediated encephalomyelitis, Infantile spasms, Intracranial hypertension, Lafora disease, Landau-Kleffner syndrome, Lennox-Gastaut syndrome, Leukodystrophy, Leukoencephalopathy with vanishing white matter, Lewy body dementia, Lissencephaly, Lyme disease - Neurological Sequelae, Megalencephaly, Meningitis, Microcephaly, Migraine, Mini-stroke (transient ischemic attack), Motor Neurone Disease - see amyotrophic lateral sclerosis, Multi-infarct dementia, Multiple sclerosis, Myoclonic Encephalopathy of infants, Myoclonus, Neurological manifestations of AIDS, Neurological sequelae of lupus, Neuronal ceroid lipofuscinosis, Neuropathy, Niemann-Pick disease, Ohtahara syndrome, Parkinson's disease, Paraneoplastic diseases, Primary Lateral Sclerosis, Prion diseases, Progressive multifocal leukoencephalopathy, Progressive Supranuclear Palsy, Rasmussen encephalitis, Restless legs syndrome, Rett syndrome, Stiff-person syndrome, Stroke, Transient ischemic attack, Traumatic brain injury, Tremor, Tuberous sclerosis, Unverricht-Lundborg disease, Uncinate epilepsy, West syndrome, Wilson's disease.

52. The inhibitor for use according to any of claims 1 to 22, the use according to any of claims 23 to 44, the pharmaceutical composition according to any of claims 45 or 46 or the use according to any of claims 47 to 50, wherein the neurologic disease is selected from a group comprising Angelman syndrome, Attention deficit hyperactivity disorder, Autism spectrum, Brain injury, Brain tumor, Creutzfeldt-Jakob disease, Down syndrome, Dravet syndrome, Encephalitis, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Head injury, Herpes zoster, Hypoxia, Immune-Mediated encephalomyelitis, Infantile spasms, Lafora disease, Landau-Kleffner syndrome, Lennox-Gastaut syndrome, Leukodystrophy, Leukoencephalopathy with vanishing white matter, Lissencephaly, Lyme disease - Neurological Sequelae, Meningitis, Multiple sclerosis, Myoclonic Encephalopathy of infants, Myoclonus, Neurological sequelae of lupus, Ohtahara syndrome, Prion diseases, Rasmussen encephalitis, Rett syndrome, Traumatic brain injury, Tuberous sclerosis, Unverricht-Lundborg disease, Uncinate epilepsy or West syndrome.

53. The inhibitor for use according to any of claims 1 to 22, the use according to any of claims 23 to 44, the pharmaceutical composition according to any of claims 45 or 46 or the use according to any of claims 47 to 50, wherein the neurologic disease is selected from the group comprising epilepsy, epileptogenesis, seizures and convulsions.

54. The inhibitor for use according to any of claims 1 to 22, the use according to any of claims 23 to 44, the pharmaceutical composition according to any of claims 45 or 46 or the use according to any of claims 47 to 50, wherein the type of epilepsy is selected from the group comprising generalized seizures, focal seizures and seizures of unknown origin.

55. The inhibitor for use according to any of claims 1 to 22, the use according to any of claims 23 to 44, the pharmaceutical composition according to any of claims 45 or 46 or the use according to any of claims 47 to 50, wherein the neurologic disease is temporal lobe epilepsy (TLE).